User:Marek Malecki MD/sandbox

Antibody-vaccine engineered construct

Antibody-vaccine engineered construct abbreviated AVEC is a biomolecularly engineered molecule consisting of the two main components: (A) antibody; (B) vaccine. (A) The antibody component is guiding AVEC to the targeted molecule, e.g., to epidermal growth factor receptor 2 (HER2) on breast cancer cells. (B) The vaccine component is eliciting immune response in a vaccinated person, e.g., immune response against the against hepatitis B virus (HBV) vaccine mounted by the prophylactic immunity gained by vaccination.

Mechanism of action of AVEC relies upon prophylactic immunity acquired through the vaccination against microbials (e.g., viruses, bacteria, etc) being redirected, amplified, and accelerated against the cancer cells, viruses, or bacteria. For example, a person vaccinated against hepatitis B virus has developed prophylactic immunity against HBV infection. If, when this person is diagnosed with HER2+ breast cancer, then receives AVEC, which is consisting of the antibody against HER2 and vaccine against HBV (AVEC: anti-HER2 - HBV). Therefore, the prophylactic immunity against HBV is redirected against cancer. By comparison, AVEC attracts the components of the immune response like a lightning-rod attracts the thunderbolts during storms. AVEC anchored on the targeted cells engages cellular immunity and the humoral elements of the immune system. Natural killer cells and cytotoxic lymphocytes eliminate the cancer cells or microbes through antibody dependent cellular cytotoxicity (ADCC). Complement system assembles C1q initiated cascade to eradicate the cancer cells. 

References

New entry accompanied by COI statement (I am the designer of the new therapy and contributor of this entry).
Marek Malecki MD (talk) 13:06, 1 May 2017 (UTC)